ArticleJournal of immunology (Baltimore, Md. : 1950)2016
Generation of Immunity against Pathogens via Single-Domain Antibody-Antigen Constructs.
Article in Journal of immunology (Baltimore, Md. : 1950), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 57 citations in OpenAlex.
- Recombinant Antibody Vaccines for Targeted Antigen Delivery: Design Principles and Immunological Applications.Vaccines · 2026Review
- Nanobody-based targeted cancer therapy and immunotherapy: fear not the future.Acta pharmacologica Sinica · 2026Review
- Presentation of hemagglutinin on adjuvant-bearing self-assembling peptide nanofibers increases heterologous responses against influenza.Acta biomaterialia · 2026Article
- Development of a dendritic cell-targeted vaccine strategy using proximity-induced conjugation.Theranostics · 2026Article
- Sortase A Catalyzed Transpeptidation for Protein Bioengineering.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Review
- A monoclonal antibody that recognizes a unique 13-residue epitope in the cytoplasmic tail of HLA-E.Molecular immunology · 2024Article
- Tertiary amide bond formation by an engineered asparaginyl ligase.Chemical science · 2024Article
- Semi-synthetic nanobody-ligand conjugates exhibit tunable signaling properties and enhanced transcriptional outputs at neurokinin receptor-1.Protein science : a publication of the Protein Society · 2024Article
- Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy.Cell death & disease · 2024Review
- Biosynthesis of magnetosome-nanobody complex in Magnetospirillum gryphiswaldense MSR-1 and a magnetosome-nanobody-based enzyme-linked immunosorbent assay for the detection of tetrabromobisphenol A in water.Analytical and bioanalytical chemistry · 2024Article
- Semi-synthetic nanobody-ligand conjugates exhibit tunable signaling properties and enhanced transcriptional outputs at neurokinin receptor-1.bioRxiv : the preprint server for biology · 2023Article
- Controlling Antigen Fate in Therapeutic Cancer Vaccines by Targeting Dendritic Cell Receptors.Molecular pharmaceutics · 2023Review
- The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics.Molecular diagnosis & therapy · 2023Review
- Construction of an alpaca immune antibody library for the selection of nanobodies againstFrontiers in bioengineering and biotechnology · 2023Article
- Enzymatic C-to-C Protein Ligation.Angewandte Chemie (International ed. in English) · 2022Article
- Variegated Outcomes of T Cell Activation by Dendritic Cells in the Steady State.Journal of immunology (Baltimore, Md. : 1950) · 2022Review
- Applications of Antibody-Based Antigen Delivery Targeted to Dendritic Cells In Vivo.Antibodies (Basel, Switzerland) · 2022Review
- The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization.Molecular biology reports · 2022Review
- A comprehensive comparison between camelid nanobodies and single chain variable fragments.Biomarker research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
mAbs specific for surface proteins on APCs can serve as Ag-delivery vehicles that enhance immunogenicity. The practical use of such constructs is limited by the challenge of expressing and modifying full-sized mAbs. We generated single-domain Ab fragments (VHHs) specific for class II MHC (MHCII), CD11b, and CD36. VHH sequences were modified by inclusion of a C-terminal sortase motif to allow site-specific conjugation with various Ag payloads. We tested T cell activation using VHHs that target distinct APC populations; anti-MHCII adducts elicited strong activation of CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.